Arrayit Corporation Announces Brands Expansion of Proprietary Finger Stick Allergy Testing
November 05 2018 - 5:30AM
Sunnyvale, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation
(OTC: ARYC), a life sciences and personalized medicine
company, announces expansion of its proprietary finger stick
microarray allergy testing platform to a growing number of major
market brands. Highly automated Arrayit technology is inherently
suited to leveraging multiple brands and their unique venues and
relationships to reach a larger number of allergy patients more
quickly. Each brand serving major retail chains, large government
agencies, medical clinics and doctor offices receive the same
high-level testing support and treatment options through the
company’s Patient Data Solutions (PDS) on-line allergy testing
portal and therapeutics affiliates. Arrayit allergy brands
expansion is increasingly allowing the 250,000 primary care
physicians in the United States to more accurately diagnose and
treat an estimated 60,000,000 (60 million) American allergy
patients.
Arrayit recently completed an allergy testing pilot program for
a top retail chain, established a nationwide network of 1,700
allergy sales professionals, met with top officials at the United
States Food and Drug Administration (FDA) regarding approval of a
major product line, signed allergy testing contracts with a
consortium of 178 medical clinics, received approval for in-store
promotions by a major retailer, announced allergy testing
partnerships with major allergy therapeutics providers, received
approval for direct Medicare billing by the Centers for Medicare
and Medicaid Services (CMS), reported the sale and shipping of
clinical instrumentation to the FDA, aced three consecutive rounds
of proficiency testing with the College of American Pathologists,
launched the Patient Data Solutions allergy portal for doctors and
clinics, and celebrated 25 years of company operations. Allergy
brands expansion relies on simple, convenient and non-invasive
finger stick blood sampling to measure allergy- and asthma-related
immunoglobulin E (IgE) molecules in newborns, special needs
children, seniors, military personnel, Medicare and Medicaid
patients, and the general public.
Chief Executive Officer Rene Schena states, “Brands expansion of
our allergy testing products represents a dynamic step towards
delivering quantitative, actionable allergy test results to doctors
treating patients nationwide. Early detection of allergy and asthma
on a personalized and family-centric basis provides an excellent
value proposition with respect to preventative medicine, improved
healthcare and greater wellness.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please
visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Oct 2023 to Oct 2024